Navigation Links
Kiadis Pharma Reports Successful End of Phase II Meeting With FDA for Reviroc
Date:12/19/2007

FDA Offers Special Protocol Assessment for Reviroc

AMSTERDAM, December 19 /PRNewswire/ -- Kiadis Pharma announced today that it has successfully completed an End of Phase II meeting for Reviroc with the U.S. Food and Drug Administration (FDA). Reviroc is under development for elimination of cancer cells from an autologous graft in bone marrow transplantations for end-stage blood cancer patients. The FDA agreed that the data from the completed phase II clinical Reviroc trial is sufficient to support the start of a phase III study. The FDA offered Kiadis Pharma its Special Protocol Assessment (SPA) procedure allowing Kiadis Pharma to work directly with the FDA to optimize the clinical design of the trial.

The FDA meeting followed the successful completion of a multi centre phase II study for Reviroc showing an improved overall survival after autologous bone marrow transplantation in Non-Hodgkin's lymphoma patients. The phase III clinical trial design for Reviroc will focus on patients with Large B cell lymphoma. Kiadis Pharma anticipates filing of the IND, SPA request and Orphan Drug Designation application with the FDA within the next few weeks.

"We are very pleased with the outcome of the End of Phase II meeting with the FDA and with the possibility to access the FDA's Special Protocol Assessment program. Together with the strong support by our principal investigators we are well prepared to design a clear path towards marketing authorization for Reviroc," said Manja Bouman, CEO Kiadis Pharma.

About Reviroc

Reviroc is being developed as a treatment that eliminates blood cancer cells from autologous transplants for patients with end stage blood cancer. An autologous transplant uses the patient's own bone marrow to serve as a graft. Bone-marrow transplants are broadly recognized as a treatment option for patients suffering from blood cancers, such as leukemia and lymphoma. One of the limitations of autologous bone mar
'/>"/>

SOURCE Kiadis Pharma
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Hearing Scheduled in the Delaware Court of Chancery for August 27, 2007 to Establish the Valid Approval and Consummation of the Merger Between PharmAthene, Inc. and Healthcare Acquisition Corp.
2. Pharmatek Adds Cytotoxic and High-Potent Drug Development Capabilities to San Diego Laboratory
3. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
4. Skystar Bio-Pharmaceutical Announces Second Quarter 2007 Results
5. Proceedings to Affirm Merger Between PharmAthene and Healthcare Acquisition Corp Initiated in Delaware Chancery Court
6. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
7. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
8. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
9. Dragon Pharmaceutical Reports Growth in Sales and Profits during Second Quarter of 2007
10. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
11. Baxa Announces 2008 Dates for STAR Center Professional Pharmacy and Cleanroom Training
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2014)... (PRWEB) August 28, 2014 Best Sanitizers, ... for the food processing industry, is asking industry professionals ... side comparison of the E2 soap they’re currently using ... Foam Soap . Hand hygiene is critical to ... food processing environment. Six key criteria are identified to ...
(Date:8/28/2014)... devices in spintronics, an electronic which is not ... also on their spin and the spin-related magnetism. ... magnetic signals and vice versa. Recently, the research ... of Physics at Johannes Gutenberg University Mainz in ... Japan, has for the first time realised a ...
(Date:8/28/2014)... ATLANTA , Aug. 28, 2014   SunTrust ... of three industry veterans to its equity research ... "Our ongoing expansion in equity research demonstrates ... with unique insights to enhance their investment decision ... Equities at STRH.  "We continue to make significant ...
(Date:8/28/2014)... Washington, USA (PRWEB) August 27, 2014 ... next month for SPIE Laser Damage 2014 ... optical materials for high-power lasers will run 14-17 September. ... society for optics and photonics . , The premier ... for understanding laser damage to optical materials will engage ...
Breaking Biology Technology:Best Sanitizers, Inc. Asks Food Industry Professionals: With Fall Harvest On the Way, Is Your E2 Hand Soap Up to the Task? 2A new, tunable device for spintronics 2A new, tunable device for spintronics 3SunTrust Robinson Humphrey Expands Equity Research in Healthcare and Energy 2SunTrust Robinson Humphrey Expands Equity Research in Healthcare and Energy 3Laser Damage to Draw Researchers, Engineers, Scientists to 46th Annual Conference 2Laser Damage to Draw Researchers, Engineers, Scientists to 46th Annual Conference 3
... Stock Exchange Symbol: MS, EDMONTON, June 12 /PRNewswire-FirstCall/ - BioMS ... sclerosis (MS), today,announced that Mr. Kevin Giese, President and CEO, will ... San Diego,California., WHEN: ... WHERE: ...
... Raptor Pharmaceuticals Corp.,(OTC Bulletin Board: RPTP), today announced ... development subsidiary, will,present at the 2008 BIO International Convention ... Convention Center in San Diego, CA., Mr. Daley,s ... 2008 at 1:15p.m. (PT) in room 4 of the ...
... Calif., June 11 Jazz,Pharmaceuticals, Inc. (Nasdaq: ... shelf registration statement with the U.S. Securities and,Exchange ... registration,statement has been declared effective by the SEC, ... to an aggregate of $100 million of its,common ...
Cached Biology Technology:BioMS Medical to present at 2008 BIO International Convention 2Raptor Pharmaceuticals Corp. To Present at BIO 2008 International Convention 2Raptor Pharmaceuticals Corp. To Present at BIO 2008 International Convention 3Raptor Pharmaceuticals Corp. To Present at BIO 2008 International Convention 4Jazz Pharmaceuticals Files Form S-3 Registration Statements 2Jazz Pharmaceuticals Files Form S-3 Registration Statements 3
(Date:8/28/2014)... MARC (Maximizing Access to Research Careers) Program has ... Society of America,s 27th Annual Mouse Molecular Genetics ... in Pacific Grove, California. These awards are ... doctorates and scientists from underrepresented groups into the ... encourage the participation of young scientists at the ...
(Date:8/28/2014)... delivering compounds that could positively impact the ... be possible, thanks to researchers in Penn ... vaginal suppository made from the seaweed-derived food ... drug Tenofovir provides a woman-initiated, drug-delivery vehicle ... sexually transmitted infections during unprotected heterosexual intercourse, ...
(Date:8/28/2014)... Dyslexia, the most commonly diagnosed learning disability in ... that occurs when the regions of the brain ... The use of non-invasive functional neuroimaging tools has ... dyslexia. However, most prior work has focused on ... a gap in our understanding of how multiple ...
Breaking Biology News(10 mins):Sensory-tested drug-delivery vehicle could limit spread of HIV, AIDS 2Sensory-tested drug-delivery vehicle could limit spread of HIV, AIDS 3Dyslexic readers have disrupted network connections in the brain 2
... , NEW YORK, Sept. 8 Reportlinker.com announces ... catalogue. , , Carbon Dioxide ... , , This report analyzes the ... by the following segments: End-tidal Carbon Dioxide (EtCO2) Monitors, and ...
... , , REDWOOD CITY, Calif., ... authentication solutions, today announced that NCR Corporation is now ... on NCR,s next-generation integrated point-of-sale (POS) workstation, the NCR RealPOS ... which is embedded in the top of the NCR RealPOS 70 ...
... MADISON, WI, SEPTEMBER 21, 2009 -- In looking ... carefully examining the role of nitrogen fixation in delivering ... long, nitrogen fixation of the soil has involved a ... thus tying the agricultural industry to the availability and ...
Cached Biology News:Reportlinker Adds Carbon Dioxide Monitors Report 2Reportlinker Adds Carbon Dioxide Monitors Report 3Reportlinker Adds Carbon Dioxide Monitors Report 4Reportlinker Adds Carbon Dioxide Monitors Report 5Reportlinker Adds Carbon Dioxide Monitors Report 6Reportlinker Adds Carbon Dioxide Monitors Report 7Reportlinker Adds Carbon Dioxide Monitors Report 8Reportlinker Adds Carbon Dioxide Monitors Report 9NCR Embeds DigitalPersona U.are.U(R) 4500HD Fingerprint Sensor in New NCR RealPOS(TM) 70XRT Point-of-Sale Workstations 2Is nitrogen the new carbon? 2
... is a new technology for sensitive ... small amounts of DNA (5). This ... to modify the DNA, followed by ... to distinguish methylated from unmethylated DNA. ...
... used for the synthesis of 5' capped ... Substitution of cap analog for a large ... vitro transcription reaction results in the incorporation ... fraction of the transcripts. Capped mRNAs are ...
... Incubator/Shaker HT is designed for ... Incubator/Shaker HT is ideal for ... and primer extension assays. The ... as a one-cabinet model, allowing ...
The iEMS Incubator/Shaker is a high performance microplate incubator and orbital shaker. Its superior temperature control and efficient orbital shaking reduce incubation times. It can incubate up to ...
Biology Products: